Business
Merck’s COVID-19 pill cuts risk of death, hospitalisation by half in study – Sydney Morning Herald
Merck and partner Ridgeback Biotherapeutics plan to seek US emergency use authorisation for the pill as soon as possible.
Merck & Co Incs experimental oral drug for COVID-19, molnupiravir, reduced by around 50 per cent the chance of hospitalisation or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
Merck and partner…
Continue Reading
-
Noosa News18 hours agoQantas plane windscreen smashed at Brisbane Airport
-
Business20 hours agoWhy this speculative ASX stock could rise 100%+
-
General21 hours agoNSW government announces measures to fast-track rental supply in Greater Sydney and beyond
-
Noosa News19 hours agoBrisbane news live: Brisbane city streets shut due to protests | How much your rates will change